{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,19]],"date-time":"2026-08-19T20:06:14Z","timestamp":1787169974946,"version":"build-2736575974"},"reference-count":14,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"4","content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2022,10]]},"abstract":"<jats:sec>\n                    <jats:title>PURPOSE:<\/jats:title>\n                    <jats:p>The objective of this study was to evaluate interleukin-6 (IL-6) tear concentration and clinical outcome in patients with moderate-to-severe bacterial corneal ulcers post autologous platelet-rich plasma (PRP) eye drop therapy.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>MATERIALS AND METHODS:<\/jats:title>\n                    <jats:p>This was a pre\u2013post designed study involving 21 moderate-severe corneal ulcer patients who got autologous PRP eye drop. Subjects were got autologous PRP eye drop as adjuvant therapy. Patients with moderate-to-severe infectious bacterial corneal ulcers were included in this study. Tear sampling was performed before therapy using sterile Schirmer paper from conjunctival inferior fornix. PRP therapy was performed for 7 days. Data recording and tear sampling were then performed at day 0 (pre-PRP), day 7 (D+7), and day 14 (D+14) after PRP therapy. Data recording included presence of pericorneal injection, blepharospasm, size of corneal defects, and hypopyon.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>RESULTS:<\/jats:title>\n                    <jats:p>\n                      There was a decrease in IL-6 tear concentration by day 14 after PRP therapy (\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      &lt; 0.001). IL-6 concentration at day 7 after therapy (7525.67 \u00b1 7092 pg\/mL) tended to be lower before therapy (10,599 \u00b1 6158 pg\/mL), but not statistically significant (\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      = 0.156). The size of corneal defects decreased significantly post PRP at day 7 (\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      = 0.035) and at day 14 (\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      = 0.001). There was a significant blepharospasm at day 7 (\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      = 0.012) and day 14 (\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      &lt; 0.001). There was a significant pericorneal injection only at day 14 (\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      = 0.002). There was no significant decreased hypopyon.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>CONCLUSION:<\/jats:title>\n                    <jats:p>There was a significant reduction in IL-6 tear concentration and clinical improvement in moderate-to-severe bacterial corneal ulcers which got autologous PRP eye drop as adjuvant therapy.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.4103\/tjo.tjo_42_21","type":"journal-article","created":{"date-parts":[[2021,11,29]],"date-time":"2021-11-29T10:49:13Z","timestamp":1638182953000},"page":"457-461","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":4,"title":["Autologous platelet-rich plasma eye drop for moderate-to-severe bacterial corneal ulcers"],"prefix":"10.4103","volume":"12","author":[{"given":"Prili Olda","family":"Fitriana","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Suhardjo","family":"Pawiroranu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tri Wahyu","family":"Widayanti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yohanes Widodo","family":"Wirohadidjojo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Indra Tri","family":"Mahayana","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R2-11-20240830","doi-asserted-by":"crossref","first-page":"496","DOI":"10.3390\/proteomes3040496","article-title":"Proteomics in the study of bacterial keratitis","volume":"3","author":"Bouhenni","year":"2015","journal-title":"Proteomes"},{"key":"R3-11-20240830","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/S0896-1549(01)00017-7","article-title":"Mechanisms of corneal ulceration","volume":"15","author":"Ma","year":"2002","journal-title":"Ophthalmol Clin North Am"},{"key":"R4-11-20240830","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1155\/2017\/2457620","article-title":"Autologous platelet-rich plasma eye drops for the treatment of post-Lasik chronic ocular surface syndrome","volume":"2017","author":"Alio","year":"2017","journal-title":"J Ophthalmol"},{"key":"R5-11-20240830","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1155\/2018\/3538764","article-title":"Clinical efficacy of platelet-rich plasma in the treatment of neurotrophic corneal ulcer","volume":"2018","author":"Wr\u00f3bel-Dudzi\u0144ska","year":"2018","journal-title":"J Ophthalmol"},{"key":"R6-11-20240830","doi-asserted-by":"crossref","first-page":"1257","DOI":"10.2174\/138920112800624355","article-title":"The role of \u201ceye platelet rich plasma\u201d (E-PRP) for wound healing in ophthalmology","volume":"13","author":"Alio","year":"2012","journal-title":"Curr Pharm Biotechnol"},{"key":"R7-11-20240830","doi-asserted-by":"crossref","first-page":"544","DOI":"10.1007\/s10384-012-0175-y","article-title":"Effect of autologous platelet-rich plasma on persistent corneal epithelial defect after infectious keratitis","volume":"56","author":"Kim","year":"2012","journal-title":"Jpn J Ophthalmol"},{"key":"R8-11-20240830","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1016\/j.tjo.2014.09.001","article-title":"Easy-to-prepare autologous platelet-rich plasma in the treatment of refractory corneal ulcers","volume":"5","author":"Wu","year":"2015","journal-title":"Taiwan J Ophthalmol"},{"key":"R9-11-20240830","doi-asserted-by":"crossref","first-page":"8549","DOI":"10.1167\/iovs.11-7956","article-title":"Role of the IL-6 classic- and trans-signaling pathways in corneal sterile inflammation and wound healing","volume":"52","author":"Ebihara","year":"2011","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"R10-11-20240830","doi-asserted-by":"crossref","first-page":"27","DOI":"10.4103\/0301-4738.29491","article-title":"A pilot study on the infiltrating cells and cytokine levels in the tear of fungal keratitis patients","volume":"55","author":"Vasanthi","year":"2007","journal-title":"Indian J Ophthalmol"},{"key":"R11-11-20240830","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1002\/emmm.201200221","article-title":"Identification of the HSPB4\/TLR2\/NF-\u03baB axis in macrophage as a therapeutic target for sterile inflammation of the cornea","volume":"4","author":"Oh","year":"2012","journal-title":"EMBO Mol Med"},{"key":"R12-11-20240830","article-title":"The role of Jankovic spasm grading, orbicularis oculi muscle function and functional improvement scale pre-and post-treatment in dosing botulinum toxin A in treatment of essential blepharospasm, Meige's syndrome and Hemifacial spasm","volume":"3","author":"Koirala","year":"2020","journal-title":"Acta Sci Ophthalmol"},{"key":"R13-11-20240830","doi-asserted-by":"crossref","first-page":"1574","DOI":"10.1080\/02713683.2017.1377261","article-title":"Conjunctival tear layer temperature, evaporation, hyperosmolarity, inflammation, hyperemia, tissue damage, and symptoms: A review of an amplifying cascade","volume":"42","author":"McMonnies","year":"2017","journal-title":"Curr Eye Res"},{"key":"R14-11-20240830","first-page":"1421","article-title":"Changes in interleukin-6 tear concentration and clinical outcome in moderate-to-severe bacterial corneal ulcers after corneal collagen cross-linking","volume":"11","author":"Erlangga","year":"2018","journal-title":"Int J Ophthalmol"},{"key":"R15-11-20240830","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1038\/s41536-021-00126-2","article-title":"The common YAP activation mediates corneal epithelial regeneration and repair with different-sized wounds","volume":"6","author":"Li","year":"2021","journal-title":"NPJ Regen Med"}],"container-title":["Taiwan Journal of Ophthalmology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/10.4103\/tjo.tjo_42_21","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,19]],"date-time":"2026-08-19T19:15:54Z","timestamp":1787166954000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/10.4103\/tjo.tjo_42_21"}},"subtitle":["Changes in interleukin-6 tear concentration and clinical outcomes"],"short-title":[],"issued":{"date-parts":[[2022,10]]},"references-count":14,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2022]]}},"URL":"https:\/\/doi.org\/10.4103\/tjo.tjo_42_21","relation":{},"ISSN":["2211-5056"],"issn-type":[{"value":"2211-5056","type":"print"}],"subject":[],"published":{"date-parts":[[2022,10]]}}}